Polypeptide-lipid nanocomposite for delivering genetic material, preparation and application

Through the nanocomplex of cyclic polypeptide and lipid combination, the problems of instability, high toxicity and difficulty in processing large DNA fragments in gene delivery technology are solved, and efficient and safe delivery of nucleic acids is achieved, especially in the delivery of mRNA and in vivo. siRNA has achieved significant results.

CN119015432APending Publication Date: 2024-11-26SUZHOU HEALIRNA BIOTECHNOLOGY CO LTD
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202310607564.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-05-26
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

The existing gene delivery technology has the problems of RNA instability, high toxicity, strong immune response and difficulty in dealing with large DNA fragments, especially for the delivery of mRNA.

Method used

Design a nanocomplex that combines cyclic polypeptides with lipids. The polypeptides assume partial delivery function, reduce the amount of lipid components, and use cyclic peptides to provide nucleic acid packaging and protection functions. Lipids are mediated through membrane fusion or permeabilization. The nucleic acid is transported into the cytoplasm and can be designed as cell type-specific or receptor-specific to improve delivery effects.

Benefits of technology

It realizes effective delivery of siRNA and mRNA in vitro and in vivo, improves cell uptake efficiency, reduces toxicity and immune response, improves the off-target effect of the liver, and enhances the processing ability of large fragments of nucleic acids.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119015432A_ABST
    Figure CN119015432A_ABST
Patent Text Reader

Abstract

The invention relates to a polypeptide-lipid nanocomposite for delivering genetic materials, preparation and application. A novel delivery carrier formula combining the cyclic polypeptide and the lipid is designed, through the synergistic effect of the two components, the dosage of the lipid component is reduced, and the polypeptide is adopted to undertake part of the delivery function. The vector is not necessarily required to have overall positive charges, so that bad serum interaction can be reduced. The cyclic peptide component provides a nucleic acid packaging function, and can protect DNA or RNA from being influenced by intracellular or extracellular degradation, endosome or other modes. The lipid component mediates interaction with the endosomal lipid bilayer through membrane fusion or permeabilization, reduces endosomal or lysosomal degradation, and allows nucleic acids to be transported into the cytoplasm. Meanwhile, the cyclopeptide component can be designed to have cell type specificity or cell surface receptor specificity, so that the strong liver off-target effect of the current liposome is improved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of drug delivery, and in particular to a polypeptide-lipid nanocomplex for delivering genetic material, and its preparation and use. Background Art

[0002] Gene transfection is a technology that transfers or transports nucleic acids with biological functions into cells and allows the nucleic acids to maintain their biological functions in cells. Gene vectors refer to a tool for introducing exogenous therapeutic genes into biological cells. Although most cells can spontaneously take up nucleic acids, the efficiency is very low and saturated at low doses. In addition, due to the presence of a large number of RNases (RNases) in nature, RNA is very unstable both in vivo and in vitro and is easily degraded. Therefore, suitable preparations are needed to protect nucleic acids from extracellular RNase-mediated degradation and promote their entry into cells.

[0003] Delivery systems for intracellular genetic material can be divided into three major categories, namely systems involving direct injection of naked DNA or RNA, systems using viruses or genetically modified viruses, and systems using non-viral delivery agents. Each has its advantages and disadvantages. Although viruses have the advantages of high efficiency and high cell selectivity as delivery agents, they have the disadvantages of toxicity, inflammatory response, and difficulty in handling large DNA fragments.

[0004] Non-viral gene delivery systems are based on the electrostatic interaction between the negatively charged phosphate backbone of DNA or RNA and cationic lipids, peptides or other polymers to compress genetic material into nanoparticles. Compared with viruses, the use of non-viral transfection vectors containing lipids can cause lower toxicity, especially lower immunogenicity; reasonable and effective targeting and enhanced packaging capabilities, such as the ability to handle large fragments of nucleic acid materials. Unfortunately, especially for mRNA, the current delivery effect still has a demand for more efficient delivery, and according to some liposome delivery systems that have seen clinical information, some toxicity and immune responses caused by the lipids themselves have been noted. Summary of the invention

[0005] As a linear molecule, polypeptides can form intramolecular self-cross-linking structures such as rings and staplers through chemical modification or biological expression. The cyclized polypeptide can effectively prolong its own half-life and enhance its structural stability. Secondly, the hydrophobic structure provided after cyclization can effectively enhance the cell's uptake of cyclic peptides. Finally, after cyclization, the peptide can effectively enhance its ability to escape from endosomes, thereby improving the release of genetic material. Compared with lipids, polypeptides are more efficient, safer, and more tolerable. They also have the advantages of higher selectivity and less accumulation in the body.

[0006] Based on the above characteristics, a new delivery carrier formula combining cyclic peptides and lipids was designed. Through the synergistic effect of the two components, the dosage of the lipid component was reduced, and the peptide was used to undertake part of the delivery function. The carrier does not necessarily need to have an overall positive charge, so adverse serum interactions can be reduced. The cyclic peptide component provides nucleic acid packaging function, which can protect DNA or RNA from intracellular or extracellular degradation, endosomes or other means. The lipid component mediates the interaction with the endosomal lipid bilayer through membrane fusion or permeabilization, reduces endosomal or lysosomal degradation, and allows nucleic acid transport into the cytoplasm. At the same time, the cyclic peptide component can also be designed to be cell type specific or cell surface receptor specific, thereby improving the current strong liver off-target effect of liposomes.

[0007] To solve the above problems, the present invention provides a combination form (ingredient type) of a polypeptide-lipid nanocomplex for delivering nucleic acids to cells in a non-viral manner. The polypeptide-lipid nanocomplex may optionally contain a structural lipid and other lipid components at a molar concentration of 20% to 100% based on the amount of total lipids to form effective protection for nucleic acids. (ingredient ratio) In a third aspect, the present invention provides a transfection complex that can effectively deliver siRNA and mRNA into cells in vitro (in vitro application). In a fourth aspect, the present invention provides a delivery vector that can deliver siRNA and mRNA to muscles, liver, and extrahepatic organs or tissues in vivo (in vivo application).

[0008] In a first aspect, the present invention provides a polypeptide-lipid nanocomplex for delivering genetic material, comprising:

[0009] (1) Nucleic acid;

[0010] (2) a polypeptide, wherein the mass percentage of the polypeptide in the complex is 5% to 75%, and the polypeptide is a single polypeptide or a combination of at least two polypeptides;

[0011] (3) lipid components, the lipid components include:

[0012] a. structural lipids, wherein the proportion of structural lipids in the complex is about 5 mol% to 80 mol%,

[0013] b. transmembrane lipids, wherein the transmembrane lipids account for about 0 mol% to 50 mol% of the complex.

[0014] c. Conjugated lipids, wherein the proportion of the conjugated lipids in the complex is about 0 mol%-3 mol%.

[0015] As a preferred embodiment of the polypeptide-lipid nanocomplex described in this patent, the mass percentage of the polypeptide in the particle is 12%-50%.

[0016] As a preferred embodiment of the polypeptide-lipid nanocomplex described in this patent, the length of the polypeptide comprises 2-100 amino acids, and the amino acid sequence in the polypeptide is derived from a natural polypeptide or an artificially designed polypeptide.

[0017] As a preferred embodiment of the polypeptide-lipid nanocomplex described in this patent, the polypeptide contains a certain proportion of polar amino acids, and the mass ratio of polar amino acids to the polypeptide ranges from 10% to 80%; preferably, the mass ratio of polar amino acids to the polypeptide ranges from 30% to 65%.

[0018] As a preferred embodiment of the polypeptide-lipid nanocomplex described in this patent, the polar amino acids include positively charged amino acids, wherein the mass ratio of the positively charged amino acids to the polar amino acids is in the range of 0%-100%. Further preferably, the mass ratio of the positively charged amino acids to the polar amino acids is in the range of 25%-100%.

[0019] As a preferred embodiment of the polypeptide-lipid nanocomplex described in this patent, the amino acid sequence is derived from a natural polypeptide, and its structure can be uncyclized or cross-linked into a ring by introducing cleavable chemical bonds. The cross-linking site can be the cyclization of the entire polypeptide or the cyclization of a certain region.

[0020] As a preferred embodiment of the polypeptide-lipid nanocomplex described in this patent, the amino acid sequence is derived from one or more of cell penetrating peptides, antimicrobial peptides, endosomal escape peptides, adhesion peptides, targeting peptides, natural cyclic peptides and proteins.

[0021] As a preferred embodiment of the polypeptide-lipid nanocomplex described in this patent, the sequence of the cell penetrating peptide includes, but is not limited to, one or more of a PTD-based peptide, an amphipathic peptide, a polyarginine-based peptide, an MPG peptide, a CADY peptide, or a VEPEP peptide. Preferably, the VEPEP peptide includes a VEPEP-3 peptide, a VEPEP-4 peptide, a VEPEP-5 peptide, a VEPEP-6 peptide, a VEPEP-9 peptide, and the like.

[0022] As a preferred embodiment of the polypeptide-lipid nanocomplex described in this patent, the cell penetrating peptide further comprises histones, including but not limited to H2A or H4 and the like.

[0023] As a preferred embodiment of the polypeptide-lipid nanocomplex described in this patent, the antimicrobial peptide sequence includes but is not limited to antimicrobial derived cationic peptides. Preferably, the antimicrobial peptide sequence is but is not limited to one or more of butofolin-2, magaininII, cecropin, andropin, moricin, ceratototoxin, melittin, bombinin, brevinin-1, esculentins, CAP18, LL37, Bac715-24 / BAC715-24, Bac1-7, Bac1-15, Bac1-17, Bac1-24, Bac5-24, Bac7-24, Bac9-24, Bac11-24, Bac13-24, Bac15-24, SynB1, SynB3, SynB5, dermaseptin S4, abaecin, apidaecin, prophenin and indole insecticide.

[0024] As a preferred embodiment of the polypeptide-lipid nanocomplex described in this patent, the endosomal escape peptide sequence includes but is not limited to hCT-derived peptides, such as hCT9-32, hCT12-32, hCT15-32, hCT18-32 or hCT21-32, etc.

[0025] As a preferred embodiment of the polypeptide-lipid nanocomplex described in this patent, the targeting peptide includes but is not limited to one or more of RGD, RGD peptide, transferrin receptor peptide, folic acid, signal peptide or signal sequence, localization signal or sequence, nuclear localization signal or sequence (NLS), receptor ligand, synthetic ligand and RGD peptide mimetic analog; or

[0026] As a preferred embodiment of the polypeptide-lipid nanocomplex described in this patent, natural cyclic peptides include but are not limited to one or more of cyclosporin-A, gramicidin-S, vancomycin and daptomycin, aplidine, Rubiaceae type cyclic peptides (RA-V, 6 and RA-VIII) and Asteraceae type cyclic peptides (astin-C); or

[0027] As a preferred embodiment of the polypeptide-lipid nanocomplex described in this patent, the protein includes but is not limited to one or more of protamine, lactoferrin, histone, transferrin and affibody small protein.

[0028] As a preferred embodiment of the polypeptide-lipid nanocomplex described in this patent, the amino acid sequence in the polypeptide is derived from an artificially designed polypeptide, and the polypeptide is an uncyclized polypeptide of an artificially designed repetitive or non-repetitive amino acid sequence, preferably the HL series peptide.

[0029] As a preferred embodiment of the polypeptide-lipid nanocomplex described in this patent, the amino acids in the polypeptide include positively charged amino acids, and the positively charged amino acids can be selected from one or more of K (lysine), R (arginine), H (histidine) and O (ornithine); the configuration of the positively charged amino acids includes a natural L-configuration or a non-natural D-configuration.

[0030] As a preferred embodiment of the polypeptide-lipid nanocomplex described in this patent, the structure of the amino acid sequence in the polypeptide includes a linear structure, a branched structure or a combination according to different functional domains, and the spatial structure of the polypeptide can be unmodified or cross-linked into a ring through cleavable bonds within the molecule to form a cyclic polypeptide.

[0031] As a preferred embodiment of the polypeptide-lipid nanocomplex described in this patent, the cyclic polypeptide contains at least one or more cyclic structures, and its cyclization method includes cleavable chemical bonds or relatively stable chemical bonds, and the proportion of amino acids involved in the cyclization is 30%-100% of the overall sequence.

[0032] As a preferred embodiment of the polypeptide-lipid nanocomplex described in this patent, the construction of the cyclic polypeptide ring region may include completely polar amino acids, or polar and non-polar amino acids arranged alternately, completely non-polar amino acids, or form a ring structure as a whole.

[0033] As a preferred embodiment of the polypeptide-lipid nanocomplex described in this patent, the lipid component can be a structural lipid, a transmembrane lipid, a conjugated lipid, with a single lipid being used or compounded in a certain ratio.

[0034] As a preferred embodiment of the polypeptide-lipid nanocomplex described in this patent, the structural lipid is a lipid used for structural filling, and the mass percentage of the structural lipid in the nanocomplex is 5%-70%.

[0035] As a preferred embodiment of the polypeptide-lipid nanocomplex described in this patent, the structural lipids include but are not limited to cholesterol and other steroid derivatives or phospholipids.

[0036] As a preferred embodiment of the polypeptide-lipid nanocomplex described in this patent, cholesterol and its derivatives include but are not limited to one or more of cholesterol, non-sterols, sitosterol, ergosterol, campesterol, stigmasterol, brassicasterol, tomatidine, tomatidine, ursolic acid, α-tocopherol and corticosteroids.

[0037] As a preferred embodiment of the polypeptide-lipid nanocomplex described in this patent, the phospholipids include, but are not limited to, one or more of phosphatidylcholine, phosphatidylethanolamine, sphingomyelin, ceramide, sterol and their derivatives.

[0038] As a preferred embodiment of the polypeptide-lipid nanocomplex described in this patent, the transmembrane lipid has the property of assembling with negatively charged biomolecules. The transmembrane lipid can combine with cargo or polypeptide molecules through electrostatic forces to form a nanostructure of a certain size. At the same time, the transmembrane lipid itself carries a charge or responds to the environment, which can promote the escape of the endosomal structure during the intracellular delivery process.

[0039] As a preferred embodiment of the polypeptide-lipid nanocomplex described in this patent, the transmembrane lipids include but are not limited to cationic lipids, HLV series lipids, ionizable lipids and transmembrane lipids containing inorganic counter ion pairs; among them, the HLV series lipids are the substances in the patent with patent number 202310038713.6.

[0040] As a preferred embodiment of the polypeptide-lipid nanocomplex described in this patent, the cationic lipids include DTDTMA (ditetradecyltrimethylammonium), DOTMA (2,3-dioleyloxypropyl-1-trimethylammonium) or DHDTMA (dihexadecyltrimethylammonium) and the like.

[0041] As a preferred embodiment of the polypeptide-lipid nanocomplex described in this patent, ionizable lipids include but are not limited to DLin-MC3-DMA (4-(N,N-dimethylamino)butyric acid (dialene) methyl ester), SM-102 (8-[(2-hydroxyethyl) [6-oxo-6-(undecyloxy) hexyl] amino] octanoic acid 1-octylnonyl ester), ALC-0315 ((4-hydroxybutyl) azadialkyl) bis (hexane 6,1-diyl) bis (2-hexyldecanoate) and the like.

[0042] As a preferred embodiment of the polypeptide-lipid nanocomplex described in this patent, the transmembrane lipid containing an inorganic counter ion pair is preferably an inorganic counter ion, especially a pharmaceutically acceptable anion, such as chloride ion or bromide ion.

[0043] As a preferred embodiment of the polypeptide-lipid nanocomplex described in this patent, the mass percentage of the transmembrane lipid in the complex ranges from 5% to 65%.

[0044] As a preferred embodiment of the polypeptide-lipid nanocomplex described in this patent, conjugated lipids are lipids used to prevent particle aggregation, and the conjugated lipids include but are not limited to polyethylene glycol (PEG), polysarcosine, polylactic acid, polycarboxybetaine or lipid conjugates of polypeptides, etc.

[0045] As a preferred embodiment of the polypeptide-lipid nanocomplex described in this patent, PEG-conjugated lipids include but are not limited to PEG-diacylglycerol (PEG-DAG), PEG-dialkoxypropyl (PEG-DAA) conjugates or mixtures thereof, etc.

[0046] As a preferred embodiment of the polypeptide-lipid nanocomplex described in this patent, the average molecular weight of PEG in the PEG-conjugated lipid is about 2000 Daltons.

[0047] As a preferred embodiment of the polypeptide-lipid nanocomplex described in this patent, the mass percentage of PEG-conjugated lipid in the complex ranges from 0.5% to 3%.

[0048] As a preferred embodiment of the polypeptide-lipid nanocomplex described in this patent, the lipid component includes any one or a combination of structural lipids, transmembrane lipids, and conjugated lipids.

[0049] The present invention provides a polypeptide-lipid nanocomplex, comprising:

[0050] (1) Nucleic acid;

[0051] (2) a polypeptide, wherein the polypeptide accounts for about 7% to 54% by weight of the complex;

[0052] (3) Structural lipids, wherein the structural lipids are cholesterol or its derivatives, and the cholesterol or its derivatives account for about 46%-93% of the mass percentage of the complex.

[0053] The present invention provides a polypeptide-lipid nanocomplex, comprising:

[0054] (1) Nucleic acid;

[0055] (2) a polypeptide, wherein the polypeptide accounts for about 12% to 69% by weight of the complex;

[0056] (3) Structural lipids, which are phospholipids, and the mass percentage of phospholipids in the complex is about 31%-88%.

[0057] The present invention provides a polypeptide-lipid nanocomplex comprising:

[0058] (1) Nucleic acid;

[0059] (2) a polypeptide, wherein the polypeptide accounts for about 10% to 87% by weight of the complex;

[0060] (3) The structural lipids include phospholipids, cholesterol or derivatives thereof, wherein the mass percentage of phospholipids in the complex is about 13%-70%, and the mass percentage of cholesterol or derivatives thereof in the complex is about 36%-90%.

[0061] The present invention provides a polypeptide-lipid nanocomplex, comprising:

[0062] (1) Nucleic acid;

[0063] (2) a polypeptide, wherein the polypeptide accounts for about 40% to 84% by weight of the complex;

[0064] (3) the membrane-penetrating lipid is a cationic lipid, and the cationic lipid accounts for about 3% to 21% by weight of the complex;

[0065] (4) The structural lipid is cholesterol or its derivatives, and the mass percentage of cholesterol or its derivatives in the complex is about 6%-39%.

[0066] The present invention provides a polypeptide-lipid nanocomplex, comprising:

[0067] (1) Nucleic acid;

[0068] (2) a polypeptide, wherein the polypeptide accounts for about 26% to 74% by weight of the complex;

[0069] (3) the membrane-penetrating lipid is a cationic lipid, and the mass percentage of the cationic lipid in the complex is about 13%-49.3%;

[0070] (4) The structural lipid is cholesterol or its derivatives, and the mass percentage of cholesterol or its derivatives in the complex is about 8.6%-38.6%.

[0071] The present invention provides a polypeptide-lipid nanocomplex, comprising:

[0072] (1) Nucleic acid;

[0073] (2) a polypeptide, wherein the polypeptide accounts for about 44% to 86% by weight of the complex;

[0074] (3) the membrane-penetrating lipid is a cationic lipid, and the cationic lipid accounts for about 6% to 24% by weight of the complex;

[0075] (4) The structural lipids include phospholipids, cholesterol or derivatives thereof, wherein the mass percentage of phospholipids in the complex is about 3%-11%, and the mass percentage of cholesterol or derivatives thereof in the complex is about 4%-21%.

[0076] The present invention provides a polypeptide-lipid nanocomplex, comprising:

[0077] (1) Nucleic acid;

[0078] (2) a polypeptide, wherein the polypeptide accounts for about 7% to 66% by weight of the complex;

[0079] (3) the membrane-penetrating lipid is a cationic lipid, and the mass percentage of the cationic lipid in the complex is about 17%-46%;

[0080] (4) the structural lipids include phospholipids, cholesterol or derivatives thereof, wherein the mass percentage of phospholipids in the complex is about 3%-27%, and the mass percentage of cholesterol or derivatives thereof in the complex is about 13%-36%;

[0081] (5) Conjugated lipids, wherein the mass percentage of the conjugated lipids in the complex is about 1%-3%.

[0082] The polypeptide-lipid nanocomplex of the present invention is brought into contact with cells.

[0083] As a preferred embodiment, the cell is a mammalian cell.

[0084] The polypeptide-lipid nanocomplex of the present invention is administered to a mammalian subject.

[0085] As a preferred embodiment, the mammalian subject is selected from the group consisting of oral, intranasal, intravenous, intraperitoneal, intramuscular, intraarticular, intralesional, intratracheal, subcutaneous or intradermal administration.

[0086] In a second aspect, the present invention also provides a polypeptide-lipid nanocomplex for non-viral delivery of nucleic acid to cells, comprising a polypeptide and a lipid component as defined in the first aspect of the present invention, wherein the lipid component comprises a structural lipid, a transmembrane lipid, and a conjugated lipid. The polypeptide-lipid nanocomplex of the first aspect of the present invention may optionally comprise a structural lipid at a molar concentration of 20% to 80% based on the total amount of the lipid component, which can effectively protect the nucleic acid.

[0087] In a third aspect, the present invention provides a transfection complex that can effectively deliver nucleic acid into cells in vitro, comprising the polypeptide-lipid nanocomplex of the first aspect or the second aspect of the present invention and a nucleic acid. The nucleic acid is advantageously RNA, especially mRNA.

[0088] In a fourth aspect, the present invention provides a delivery vector that can deliver siRNA and mRNA to muscle, liver, and extrahepatic organs or tissues in vivo.

[0089] The technical solution provided by the present invention has at least one or more of the following beneficial effects:

[0090] The novel delivery carrier formula of the combination of cyclic peptide and lipid reduces the amount of lipid component through the synergistic effect of the two components, and uses the peptide to undertake part of the delivery function. The carrier does not necessarily need to have an overall positive charge, so it can reduce adverse serum interactions.

[0091] The polypeptide component provides nucleic acid packaging function, protecting the DNA or RNA from intracellular or extracellular degradation, endosomes or other means.

[0092] The lipid components mediate interactions with the endosomal lipid bilayer via membrane fusion or permeabilization, reducing endosomal or lysosomal degradation and allowing transport of nucleic acids into the cytoplasm.

[0093] At the same time, the cyclic peptide component can also be designed to be cell type specific or cell surface receptor specific, thereby improving the current strong liver off-target effect of liposomes. BRIEF DESCRIPTION OF THE DRAWINGS

[0094] Figure 1 Display the peptide HPLC-MS purity test results;

[0095] Figure 2 Display the results of HPLC purity test of lipid components;

[0096] Figure 3 Shows the agarose gel electrophoresis results at different mass ratios of polypeptide to mRNA;

[0097] Figure 4 It was shown that peptide lipid nanoparticles can deliver siRNA into cells;

[0098] Figure 5 Show the effect of replacing different lipid components with different characteristics on the mRNA delivery effect;

[0099] Figure 6 Display the expression levels of polypeptide lipid particles composed of various types of polypeptides in cells;

[0100] Figure 7 Shows the expression levels of peptide lipid particles composed of various types of peptides in mice;

[0101] Figure 8 Show the effect of changes in the proportion of each component in the formula on the expression level of cells;

[0102] Fig. 9 Show the effect of replacing different lipid components on mRNA delivery efficiency;

[0103] Fig.10 Shows the expression level of the peptide lipid particle system library A prescription in cells;

[0104] Fig.11 Shows the expression level of the peptide lipid particle system B library prescription in cells;

[0105] Fig.12 Display the expression levels of all prescriptions of the peptide lipid particle system in cells;

[0106] Fig.13 Shows the expression level of target fluorescent protein of polypeptide lipid particles in mice. Example

[0107] The present invention is further described in detail below in conjunction with specific embodiments so that those skilled in the art can better understand the present invention and thus make a clearer and more definite definition of the protection scope of the present invention.

[0108] Example 1. Polypeptide preparation

[0109] The main chain was connected sequentially from the C-terminus by solid phase synthesis, and an excess of protective amino acids and condensation reagents were used to ensure that each step of the reaction was complete, and then the two cysteines formed a disulfide bond. Subsequently, the protective group and the peptide resin were cut in a trifluoroacetic acid solution, precipitated with methyl tert-butyl ether, and centrifuged to obtain a crude product, which was purified by preparative high performance liquid chromatography to obtain the target peptide.

[0110] The non-naturally occurring peptides of the present invention are produced by any previously known peptide synthesis method known to those of ordinary skill in the art, including but not limited to recombinant methods or peptide synthesis chemistry, such as solid phase peptide synthesis. Solid phase synthesis methods (Marrifield, "Journal of the American Chemical Society (J.Am.Chem.Soc.)", 85, 2149-2154, 1963) can be marked as only one example of such peptide synthesis methods. Currently, peptides can be produced simply and in a relatively short period of time using automatic universal peptide synthesizers based on those principles. In addition, peptides can be produced using well-known recombinant protein production techniques, which are widely known to skilled professionals. The simple synthesis method and specific process of the polypeptides of the present invention are described as follows:

[0111] (1) Resin treatment

[0112] ① Resin swelling: Select Fmoc-Arg(pbf)2-Chlorotrityl Resin (molar substitution coefficient is 0.317 mmol / g) as the starting resin, add it to a 50 ml reaction column, add DCM (dichloromethane) to soak, and drain to complete the swelling of the resin.

[0113] ② Deprotection: Add DMF (N, N-dimethylformamide) solution containing 20% ​​(g / 100ml) piperidine, stir for 30 minutes under N2 (nitrogen), filter and dry the solvent; then wash the resin with DMF (N, N-dimethylformamide) 6 times, drain and complete the deprotection of the resin.

[0114] (2) Amino acid coupling reaction

[0115] Reaction monitoring detection method: The reaction progress was monitored by the ninhydrin method.

[0116] The raw materials and reagents used are as follows:

[0117] name Feeding amount (mmol) Protect amino acids 2 O-Benzotriazole-N,N,N′,N′-tetramethyluronium tetrafluoroborate (TBTU) 2 N,N-Diisopropylethylamine (DIEA) 2

[0118] The specific operation process is as follows:

[0119] Weigh the corresponding amount of TBTU and protected amino acid into a beaker, add DMF to dissolve; then add the reaction solution to the resin after deprotection in step (1), add DIEA, pass N2 to blow for about 90 minutes, and detect by ninhydrin reaction. After the reaction is completed, remove the solvent and wash the resin with DMF 3 times. Add a DMF solution containing 20% ​​(g / 100ml) piperidine to the resin, pass N2 to continue blowing for 30 minutes, then remove the solvent and wash the resin with DMF 6 times to complete the coupling of this amino acid.

[0120] Repeat the above reaction procedure until the condensation reaction of all protected amino acids is completed. After coupling to the last protected amino acid, shrink the polypeptide, wash it with DMF, DCM, and methanol three times in sequence, and weigh it after drying. Condensation method: TBTU+DIEA, condensation agent: TBTU: 0.64g, DIEA: 0.7ml.

[0121] (3) TFA cleavage (dissociate the peptide from the resin and remove the amino acid side chain protecting groups)

[0122] The resin obtained in "(2) Amino Acid Coupling Reaction" was added to the prepared lysate (containing 86% TFA, 5% EDT (ethylenedithiol), 5% thioanisole, 3% phenol and 2% pure water) and stirred for 150 minutes. The resin and the lysate were then separated, and ether was added to the separated lysate to fully precipitate the polypeptide; the crude peptide was filtered and fully washed with ether for 6 times to obtain the crude peptide, which was purified to obtain a polypeptide sample. Other polypeptides provided by the present invention were synthesized in this way.

[0123] (4) Simple steps for purification

[0124] The crude peptide obtained in step (3) was dissolved in a mixture of acetonitrile and water in a volume ratio of 1:1, clarified and filtered, and the purity and molecular weight of the peptide were detected by liquid chromatography-mass spectrometry (HPLC-MS). Figure 1 .

[0125] Example 2. Lipid synthesis

[0126] The examples in this section are provided by way of example only and not by way of limitation.

[0127] General approach

[0128] General preparative HPLC method: HPLC purification was performed on a HPLC equipped with an evaporative light detector (ELSD). On machine U100-Test, On the rapid separation column, dichloromethane is generally used as solvent A, methanol as solvent B, methanol solution containing 7M ammonia as solvent C, petroleum ether as D, and ethyl acetate as E for purification. Figure 2 .

[0129] General LCMS methods: LCMS analysis was performed on a Thermo (LC-MS) system. Chromatography was performed on a SunFire C18, typically using water with 0.1% trifluoroacetic acid as solvent A and acetonitrile with 0.1% formic acid as solvent B.

[0130] General synthesis method:

[0131]

[0132] A solution of amine A (1.0 mmol) and aldehyde P (1.0 mmol) in EtOH (20 mL) was stirred at room temperature for 1 h. Acid C (1.0 mmol) and isonitrile I (1.0 mmol) were then added, and the reaction mixture was stirred at room temperature overnight and then concentrated to dryness under reduced pressure. The crude product was purified by preparative chromatography to obtain the corresponding compound.

[0133] Embodiment 1:

[0134] Preparation of compound 1

[0135]

[0136] At room temperature, N,N-dimethyl-1,3-diaminopropane (350 mg, 3.42 mmol) was dissolved in ethanol, nonanal (487.2 mg, 3.42 mmol) was added, and after stirring for 1 hour, intermediate C1-007 was added.

[0137] (1413.5 mg, 3.42 mmol), continued stirring for 0.5 h, added n-octyl isocyanide (477 mg, 3.42 mmol), and the reaction mixture was stirred for 16 hours. TLC monitored the completion of the reaction, evaporated the mixture under reduced pressure and purified by preparative HPLC, the purification conditions were solvent A: solvent C = 100: 0 to 90: 10 gradient program, and compound 1 (995.5 mg, 37.4% yield) was obtained as a colorless oil. Mass spectrum M+1 = 779.31.

[0138] This preparation procedure is the standard compound preparation procedure

[0139] Example 3. Gel retardation assay to detect the ability of polypeptides to compress mRNA

[0140] Prepare agarose gel with a mass volume ratio of 1% (add 50 ml of 0.5×TBE buffer solution for every 0.5 g of agarose), heat it in a microwave to fully melt it, add SYBR Safe DNA Gel Stain dye to the agarose at a ratio of 1:10000, pour it into the corresponding gel slot (9-well card slot) after fully mixing, and cool it for 20 minutes for use.

[0141] Preparation method of mRNA positive control group: Use Fluc mRNA as model mRNA, add 5μl of mRNA solution with a concentration of 100ng / μl, and then add 5μl 2X RNA Loading Buffer and mix well.

[0142] Sample group configuration method: According to the different mass ratios of polypeptide and mRNA, 2.5μl of mRNA solution with a concentration of 200ng / μl (i.e. 500ng) was mixed with 2.5ul of polypeptide solution of different masses, and 5μl of 2X RNA Loading Buffer was added to each sample after mixing for 10 minutes. After the samples were mixed, 10μl of the system was added to each well, and the gel was run for 15 minutes using a 90V voltage electrophoresis instrument, and observed with a gel imager.

[0143] Conclusion: The experimental results are as follows Figure 3 As shown, the minimum mass ratio of each polypeptide to ensure complete compression of mRNA varies depending on the properties of the polypeptide itself.

[0144] Example 4. Solution preparation and assembly method

[0145] Lipid component configuration:

[0146] Prepare storage solution: weigh the corresponding mass of each component on an electronic balance, dissolve it in ethanol, use it after it is fully dissolved, record parameters such as concentration batch number, send the sample to HPLC for testing, confirm the purity, and store it at -20℃ for future use.

[0147] Preparation of working solution: Prepare lipid premix according to the above ratio, add different volumes of storage solution, dilute with ethanol, and prepare a lipid mixture with a total lipid concentration of 9 mg / ml.

[0148] Peptide component configuration:

[0149] Preparation of storage solution: Weigh an appropriate amount of synthesized polypeptide powder, dissolve it in DEPC water, mix thoroughly, and prepare a 2 mg / ml clear colorless solution. Filter it through a 0.22 um filter and store it at -20 °C for future use.

[0150] Preparation of working solution: 2 mg / ml peptide was diluted to 0.1 mg / ml working concentration with DEPC water.

[0151] Nucleic acid component configuration:

[0152] Preparation of storage solution: After the mRNA solution is purified, it is diluted to volume with 1 mM sodium citrate pH 6.5 buffer, quantified by Nanodrop, and parameters such as concentration batch number are recorded. It is then stored at -80°C for future use.

[0153] Preparation of working solution: Dilute the mRNA solution of corresponding concentration with DEPC water to a working concentration of 0.1 mg / ml.

[0154] Particle assembly

[0155] Prepare the working solution of each component, mix the aqueous phase and the ethanol phase by microfluidic assembly, let stand at RT for 30 minutes, complete the assembly, and remove the ethanol by ultrafiltration according to the normal process to form polypeptide lipid particles.

[0156] Example 5. Characterization of the present invention

[0157] Particle size and potential: physicochemical parameters of peptide lipid particles measured by DLS

[0158] Using Fluc mRNA as a model mRNA, polypeptide lipid particles were prepared according to the preparation method described in Example 4, and the dynamic light scattering particle size (size), surface potential (Zeta Potential) and polydispersity (PDI) of the polypeptide lipid particles were tested at 25°C using a Malvern Zetasizer NanoZSE. The results are shown in the table, which show that the particle size of the polypeptide complex nanoparticles of the present invention ranges from 100nm to 200nm, has good dispersibility, and the surface charge is between mV and mV.

[0159] Encapsulation efficiency: a method for measuring the efficiency of nucleic acid encapsulation

[0160] Using Fluc mRNA as the model mRNA, polypeptide lipid particles were prepared according to the preparation method described in Example 4, and the Quant-iTRiboGreen RNA detection kit was used to determine the encapsulation efficiency of each prescription for mRNA. The specific method was referred to the kit instructions. The present invention is briefly summarized as follows: a standard solution was prepared according to the instructions, and the concentration of the formed polypeptide lipid particles was estimated. The polypeptide lipid particles were diluted 100 times with 1xTE to obtain a free phase, and the concentration of mRNA in the supernatant was measured using the Quant-iTRiboGreen RNA detection kit, which was recorded as C1; 1xTE (containing a final concentration of 5% Triton X-100) was diluted 200 times to obtain a lysis phase, and the concentration of mRNA was measured using the Quant-iTRiboGreen RNA detection kit, which was recorded as C2; the encapsulation efficiency of each prescription was calculated as follows: EE% = (C2-C1) / C2*100%

[0161] Example 6: Application of polypeptides in different delivery vectors

[0162] In order to verify the applicability of polypeptide delivery in different carriers, the currently published carrier technologies for delivering nucleic acids, LPX and Liposome and LNP, were selected to deliver nucleic acids.

[0163] 1. Peptide lipid nanoparticles to deliver siRNA

[0164] Encapsulation: Cy3-labeled siRNA was prepared and detected according to the assembly method of Example 4 and the physicochemical parameter determination method of Example 5. The transfection method was described in Example 6, and the cells were co-incubated with 293T cells. After 6 hours, the complete culture medium was replaced and cultured for 24 hours, and observed under a fluorescence microscope.

[0165] Table 1 Physicochemical parameters of polypeptide lipid particles

[0166]

[0167] Conclusion: As shown in Table 1, it is shown that polypeptide lipid particles and polypeptide lipid nanoparticles can effectively encapsulate siRNA. Figure 4 This indicates that polypeptide lipid particles can effectively deliver siRNA into cells, and the delivery efficiency is higher than that of commercial liposomes Lipo2000.

[0168] 2. Delivery of mRNA by combining different formula ratios

[0169] Fluc-mRNA was encapsulated and assembled as described in Example 4. Different types of polypeptide lipid particles were formed (see Table 2). Physical and chemical parameters were determined as described in Example 5. The transfection method was described in Example 6. 293T cells were co-incubated. After 6 hours, the complete medium was replaced and cultured for 24 hours, and the chemiluminescence intensity was detected.

[0170] Table 2 Different prescription types

[0171]

[0172] Table 3 Physicochemical parameters of polypeptide lipid particles

[0173]

[0174]

[0175] Conclusion: As shown in Table 3, peptides in different formulations and forms can effectively encapsulate nucleic acids in liposomes. Figure 5 It can be observed that different combinations of polypeptides and lipids have different degrees of improvement in mRNA delivery. Example 7. Effect of polypeptide lipid particles composed of various types of polypeptides on mRNA delivery 1. Different types of polypeptides were selected as representatives from naturally occurring polypeptides or polypeptides mentioned in patent papers, and linear polypeptides synthesized in-house were used as controls to test them with lipid components and mRNA complex particles. Table 4 provides the polypeptides used and their properties. The lipid components were compounded using ALC0315 liposomes.

[0176] Table 4 Different types of peptides

[0177]

[0178] Cell transfection with mRNA: 293T cell suspension in logarithmic growth phase was cultured at 3×10 4 The cells were divided into 96-well plates at a density of 10 cells / well and placed in a 37°C, 5% CO2 incubator for static culture. After 24 hours, the polypeptide lipid particles assembled with different polypeptides were added to each well of a 96-well plate containing 100 μl Opti-MEM culture medium at a mass of 200 ng per well, and each sample was repeated 3 wells. After 6 hours of administration, the culture medium in the 96-well plate was replaced with complete culture medium. After continuing to culture for 24 hours, 100 μl of D-Luciferin working solution (working concentration of 250 μg / ml) was added to each 96-well plate, and cultured in a 37°C incubator for 5 minutes, and the fluorescence expression intensity was tested by imaging with an enzyme marker.

[0179] Conclusion: The results are attached. Figure 6 Different types of polypeptides can show different effects in polypeptide lipid particles, and compared with other natural polypeptides or commercially used polypeptides, P1 polypeptide shows a significant improvement in mRNA delivery in polypeptide lipid particles.

[0180] 2. Select several representative prescriptions from the cell experiment for in vivo verification to observe the mRNA delivery effect. According to the assembly method of Example 4 and the physicochemical parameter determination method of Example 5, the polypeptide lipid particles were prepared and detected. Three female BALB / c mice were used in each group. Fluc mRNA was used as the model mRNA, and polypeptide complex nanoparticles containing Fluc mRNA were prepared by the method described in the present invention. The experimental group used an insulin needle to inject 50 μl of polypeptide complex nanoparticles containing 2 μg Fluc mRNA into each mouse. The administration method was intramuscular injection, and the injection site was the thigh muscle of the mouse. NC represents the blank control group, and 50 μl PBS buffer was injected intramuscularly with an insulin needle. After 6 hours of administration, an appropriate amount of substrate D-Luciferin was taken, diluted by PBS to prepare a solution with a concentration of 25 mg / ml, kept away from light for standby use, and 100 μl of substrate was injected intraperitoneally into each mouse. The mouse was placed in a small animal anesthesia box, the ventilation valve was opened, and isoflurane was released to anesthetize the mouse. 5 minutes after substrate injection, the mice were subjected to whole-body in vivo imaging bioluminescence image detection using a small animal in vivo imaging system (PerkinElmer, IVISLumina Series III). Bioluminescence images of the back of the mice were taken, and then the mice were killed, and the liver and spleen were taken to detect the fluorescence expression level of the organs.

[0181] Table 5 Physicochemical parameters of polypeptide lipid particles

[0182]

[0183] Conclusion: As shown in Table 5, the particle size distribution of several polypeptides is around 100nm, PDI is 0.1-0.2, and the potential is around +20mV. They can wrap nucleic acids well. The results are shown in the attached Figure 7 It can be observed that different types of polypeptides have different degrees of delivery effects on mRNA, among which the synthetic polypeptide P1 has a better delivery effect than other polypeptides.

[0184] Example 8. Effect of changes in the proportion of each component in the formula on the mRNA delivery effect

[0185] According to Example 7, the optimal combination of polypeptide and lipid species was determined, and the effect of changing the ratio of the two on mRNA delivery was further verified. The assembly method was as described in Example 4, the amount of polypeptide and lipid added was changed, Fluc-mRNA was encapsulated, and the transfection method was described in Example 6. It was co-incubated with 293T cells, and the complete culture medium was replaced after 6 hours for 24 hours to detect the chemiluminescence intensity.

[0186] Conclusion: The results are as follows Figure 8 As described above, by changing the added amounts of polypeptide and lipid, the delivery effect of mRNA is significantly changed, thereby determining the optimal compounding ratio of polypeptide lipid particles.

[0187] Example 9. Effect of replacement of lipid components with different characteristics on mRNA delivery effect

[0188] Different types of lipids were compounded with polypeptides to detect the effects of different types of lipid changes on the delivery effect of mRNA. The assembly method was as described in Example 4. Different liposomes were combined with linear cyclic peptide P1 to encapsulate Fluc-mRNA. The physicochemical properties of the particles were detected as described in Example 5. The transfection method was described in Example 6. 293T cells were co-incubated. After 6 hours, the complete culture medium was replaced and cultured for 24 hours to detect the chemiluminescence intensity.

[0189] Conclusion: The results are attached. Fig. 9 After replacing different types of lipids to form polypeptide lipid particles, different mRNA delivery effects were manifested at the cellular level, and compared with ALC0315, most ionizable lipids showed better mRNA delivery ability.

[0190] Example 10. DOE screening of suitable formulations for polypeptide lipid particle systems

[0191] The delivery effect of nucleic acid depends not only on the types of components in the polypeptide lipid particle system, but also on the ratio of various components in the polypeptide lipid particles. The mass ratio of mRNA and polypeptide used in the current embodiment is 1:1, and the lipid ratio uses the classic prescription of Pfizer / BioNTech. Considering that the optimal lipid ratio provided in this patent is not necessarily applicable to the ratio of ALC0315, and there are polypeptide components in the polypeptide lipid particle carrier system, it is necessary to screen out the applicable ratio range of each component in the system and the most preferred ratio range, so as to conduct experiments. In order to optimize the polypeptide lipid particle formula, linear polypeptide P1 was selected, the ratio of mRNA and polypeptide was fixed to 1:4, and ionizable lipid Va2.1-024 was selected as the experimental object, and the orthogonal experimental design (DoE) method was used to modify the molar ratio of lipid components: ionizable lipids, auxiliary lipids, and conjugated lipids to construct the first round of optimization of the formula in library A (Table 6).

[0192] Table 6 Library A (molar ratio)

[0193]

[0194]

[0195] Conclusion: The results are attached. Fig.10, changing the molar ratio of different components in the lipid component while fixing the ratio of peptide and mRNA has a significant effect on the expression of fluorescence. After a round of preliminary screening, a second round of optimization details was carried out. In order to further screen the formula, a second round of optimization was carried out. According to the ratio range of each component screened out by library A, the relative molar ratio and molar percentage were fine-tuned to construct library B (Table 7)

[0196] Table 7 Library B (molar ratio)

[0197]

[0198]

[0199] Conclusion: The results are attached. Fig.11 , under the condition of fixing the ratio of peptide and mRNA, the range boundary is expanded upward or downward according to the conclusion of library A to form library B. Different prescriptions show obvious differences. Based on this, the results of different prescriptions of library A and library B are statistically analyzed to obtain the proportion of each component of the lipid component. The results are as follows Fig.12 As shown in Table 8, changing the proportion of each component shows an obvious change trend. The proportion range of different components in this system is shown in Table 8.

[0200] Table 8 Molar ratio of different components of polypeptide lipid particles

[0201]

[0202] Example 11: Experiment on expression of target fluorescent protein by polypeptide lipid particles in mice

[0203] According to the formulation ratio obtained in Example 10, as shown in Table 9, the particle size of the polypeptide lipid nanoparticles is about 200-300 nm, the PDI (polydispersity index) is around 0.2, the Zeta (potential) is about 10, and the encapsulation rate is mostly above 80%. Several representative prescriptions were selected for in vivo verification. The assembly method was as described in Example 4, and the Fluc-mRNA was encapsulated according to the prescription ratio of each group. The physical and chemical properties of the particles were detected as described in Example 5, and the mice were administered according to the method in Example 7.

[0204] Conclusion: The results are as follows Fig.13 As shown, the polypeptide complex nanoparticles of each experimental group encapsulating Fluc-mRNA had good luciferase expression in mice, and among the experimental group prescriptions, the luciferase was superior to other prescriptions.

[0205] Table 9 Physicochemical parameters of polypeptide lipid particles

[0206]

Claims

1. A polypeptide-lipid nanocomplex, characterized in that: include: (1) Nucleic acid; (2) a polypeptide, wherein the mass percentage of the polypeptide in the complex is 5% to 75%, and the polypeptide is a single polypeptide or a combination of several polypeptides; (3) lipid components, the lipid components include: a. structural lipids, accounting for about 5 mol% to 80 mol% of the complex; b. Transmembrane lipids, accounting for about 0 mol% to 50 mol% of the complex; c. Conjugated lipids, accounting for about 0 mol%-3 mol% in the complex.

2. A polypeptide-lipid nanocomplex according to claim 1, characterized in that: The length of the polypeptide includes 2-100 amino acids, and the amino acid sequence in the polypeptide is derived from a natural polypeptide or an artificially designed polypeptide.

3. A polypeptide-lipid nanocomplex according to claim 2, characterized in that: The polypeptide contains a certain proportion of polar amino acids, and the mass ratio of polar amino acids to the polypeptide ranges from 10% to 80%; Polar amino acids include positively charged amino acids, wherein the mass ratio of positively charged amino acids to polar amino acids ranges from 0% to 100%.

4. The polypeptide-lipid nanocomplex according to claim 2, characterized in that: The amino acid sequence is derived from a natural polypeptide, and its structure may be uncyclized or cross-linked into a ring by introducing cleavable chemical bonds. The cross-linking site may be the cyclization of the entire polypeptide or a certain region.

5. The polypeptide-lipid nanocomplex according to claim 4, characterized in that: The amino acid sequence is derived from one or more of cell penetrating peptides, antimicrobial peptides, endosomal escape peptides, adhesion peptides, targeting peptides, natural cyclic peptides and proteins.

6. The polypeptide-lipid nanocomplex according to claim 5, characterized in that: The sequence of the cell penetrating peptide includes one or more of a PTD-based peptide, an amphipathic peptide, a polyarginine-based peptide, an MPG peptide, a CADY peptide, and a VEPEP peptide; or The antimicrobial peptide sequence comprises an antimicrobial derived cationic peptide; or The endosomal escape peptide sequence comprises an hCT-derived peptide; or The cell penetrating peptide comprises a histone; or The targeting peptide comprises one or more of RGD, RGD peptide, transferrin receptor peptide, folic acid, signal peptide or signal sequence, localization signal or sequence, nuclear localization signal or sequence (NLS), receptor ligand, synthetic ligand and RGD peptide mimetic analog; or Natural cyclic peptides include one or more of cyclosporin-A, gramicidin-S, vancomycin, daptomycin, aplidine, Rubiaceae type cyclic peptides (RA-V, 6 and RA-VIII) and Asteraceae type cyclic peptides (astin-C); or The protein includes one or more of protamine, lactoferrin, histone, transferrin or affibody miniprotein.

7. The polypeptide-lipid nanocomplex according to claim 2, characterized in that: The amino acid sequence in the polypeptide is derived from an artificially designed polypeptide, and the polypeptide is an uncyclized polypeptide of an artificially designed repetitive or non-repetitive amino acid sequence.

8. The polypeptide-lipid nanocomplex according to claim 7, characterized in that: The amino acids in the polypeptide include positively charged amino acids, which can be selected from one or more of K (lysine), R (arginine), H (histidine) and O (ornithine); the configuration of the positively charged amino acids includes a natural L-configuration or a non-natural D-configuration.

9. The polypeptide-lipid nanocomplex according to claim 8, characterized in that: The structure of the amino acid sequence in a polypeptide includes a linear structure, a branched structure, or a combination of different functional domains. Its spatial structure can be unmodified or cross-linked into a ring through cleavable bonds within the molecule to form a cyclic polypeptide.

10. The polypeptide-lipid nanocomplex according to claim 9, characterized in that: The cyclic polypeptide comprises at least one or more cyclic structures, and the cyclization mode thereof includes a cleavable chemical bond or a relatively stable chemical bond, and the proportion of amino acids involved in the cyclization is 30%-100% of the overall sequence.

11. The polypeptide-lipid nanocomplex according to claim 9, characterized in that: The construction of the ring region of the cyclic polypeptide may include completely polar amino acids, or polar and non-polar amino acids arranged alternately, completely non-polar amino acids, or form a ring structure as a whole.

12. The polypeptide-lipid nanocomplex according to claim 1, characterized in that: The lipid components can be structural lipids, transmembrane lipids, conjugated lipids, and a single lipid can be used or compounded in a certain ratio.

13. The polypeptide-lipid nanocomplex according to claim 12, characterized in that: The structural lipid is a lipid used for structural filling, and the mass percentage of the structural lipid in the nanocomplex is 5%-70%.

14. According to claim 13, the structured lipids include cholesterol and other steroidal derivatives or phospholipids; Cholesterol and its derivatives include one or more of cholesterol, non-sterols, sitosterol, ergosterol, campesterol, stigmasterol, brassicasterol, tomatine, tomatine, ursolic acid, α-tocopherol and corticosteroids. The phospholipids include one or more of phosphatidylcholine, phosphatidylethanolamine, sphingomyelin, ceramide, sterol and their derivatives.

15. The polypeptide-lipid nanocomplex according to claim 12, characterized in that: Transmembrane lipids have the property of assembling with negatively charged biomolecules, and can combine with cargo or polypeptide molecules through electrostatic forces to form nanostructures of a certain size. At the same time, the transmembrane lipids themselves carry charges or are charged in response to the environment, which can promote the escape of endosomal molecules during intracellular delivery. The mass percentage of the membrane-penetrating lipid in the complex ranges from 5% to 65%.

16. The polypeptide-lipid nanocomplex according to claim 23, characterized in that: Transmembrane lipids include cationic lipids, HLV series lipids, ionizable lipids and transmembrane lipids containing inorganic counter ion pairs; cationic lipids include DTDTMA (ditetradecyltrimethylammonium), DOTMA (2,3-dioleyloxypropyl-1-trimethylammonium) or DHDTMA (dihexadecyltrimethylammonium). Ionizable lipids include 4-(N,N-dimethylamino)butyric acid (diaoleyl) methyl ester (Dlin-MC3-DMA), 8-[(2-hydroxyethyl) [6-oxo-6-(undecyloxy) hexyl] amino] octanoic acid 1-octylnonyl ester (SM-102), ((4-hydroxybutyl) azadialkyl) bis (hexane 6,1-diyl) bis (2-hexyldecanoate) (ALC 0315). The membrane-penetrating lipids containing an inorganic counter ion pair include an inorganic counter ion, especially a pharmaceutically acceptable anion.

17. The polypeptide-lipid nanocomplex of claim 12, characterized in that: Conjugated lipids are lipids used to prevent particle aggregation. Conjugated lipids include lipid conjugates of polyethylene glycol (PEG), polysarcosine, polylactic acid, polycarboxybetaine, and polypeptides.

18. The polypeptide-lipid nanocomplex according to claim 17, characterized in that: PEG-conjugated lipids include, but are not limited to, PEG-diacylglycerol (PEG-DAG), PEG-dialkoxypropyl (PEG-DAA) conjugates, or mixtures thereof; The average molecular weight of PEG in the PEG-conjugated lipids is about 2000 Daltons; The mass percentage of PEG-conjugated lipid in the complex ranged from 0.5% to 3%.

19. A polypeptide-lipid nanocomplex, characterized in that: Include: (1) Nucleic acid; (2) a polypeptide, wherein the polypeptide accounts for about 7% to 54% by weight of the complex; (3) Structural lipids, wherein the structural lipids are cholesterol or its derivatives, and the cholesterol or its derivatives account for about 46%-93% of the mass percentage of the complex.

20. A polypeptide-lipid nanocomplex, characterized in that: Include: (1) Nucleic acid; (2) a polypeptide, wherein the polypeptide accounts for about 12% to 69% by weight of the complex; (3) Structural lipids, which are phospholipids, and the mass percentage of phospholipids in the complex is about 31%-88%.

21. A polypeptide-lipid nanocomplex, characterized in that: Include: (1) Nucleic acid; (2) a polypeptide, wherein the polypeptide accounts for about 10% to 87% by weight of the complex; (3) The structural lipids include phospholipids, cholesterol or derivatives thereof, wherein the mass percentage of phospholipids in the complex is about 13%-70%, and the mass percentage of cholesterol or derivatives thereof in the complex is about 36%-90%.

22. A polypeptide-lipid nanocomplex, characterized in that: Include: (1) Nucleic acid; (2) a polypeptide, wherein the polypeptide accounts for about 40% to 84% by weight of the complex; (3) the membrane-penetrating lipid is a cationic lipid, and the cationic lipid accounts for about 3% to 21% by weight of the complex; (4) The structural lipid is cholesterol or its derivatives, and the mass percentage of cholesterol or its derivatives in the complex is about 6%-39%.

23. A polypeptide-lipid nanocomplex, characterized in that: Include: (1) Nucleic acid; (2) a polypeptide, wherein the polypeptide accounts for about 44% to 86% by weight of the complex; (3) the membrane-penetrating lipid is a cationic lipid, and the cationic lipid accounts for about 6% to 24% by weight of the complex; (4) The structural lipids include phospholipids, cholesterol or derivatives thereof, wherein the mass percentage of phospholipids in the complex is about 3%-11%, and the mass percentage of cholesterol or derivatives thereof in the complex is about 4%-21%.

24. A polypeptide-lipid nanocomplex, characterized in that: Include: (1) Nucleic acid; (2) a polypeptide, wherein the polypeptide accounts for about 7% to 66% by weight of the complex; (3) the membrane-penetrating lipid is a cationic lipid, and the mass percentage of the cationic lipid in the complex is about 17%-46%; (4) the structural lipids include phospholipids, cholesterol or derivatives thereof, wherein the mass percentage of phospholipids in the complex is about 3%-27%, and the mass percentage of cholesterol or derivatives thereof in the complex is about 13%-36%; (5) Conjugated lipids, wherein the mass percentage of the conjugated lipids in the complex is about 1%-3%.

25. Contacting a cell with the polypeptide-lipid nanocomplex of any one of claims 1, 20, 22 or 24.

26. The method according to claim 37, characterized in that The cell is a mammalian cell.

27. Administering the polypeptide-lipid nanocomplex of any one of claims 1, 31, 33, 35 or 37 to a mammalian subject. wherein the mammalian subject is selected from the group consisting of oral, intranasal, intravenous, intraperitoneal, intramuscular, intraarticular, intralesional, intratracheal, subcutaneous or intradermal.

Citation Information

Cited By

  • Multivalent ionizable lipid-polypeptide as well as preparation method and application thereof

    CN119751855A